A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

The study "Reducing MRI Use in Organised Prostate Cancer Testing Using Blood-Based Biomarkers - the OPT Stockholm3 Study" ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26 ...